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NICOLETTI ET AL 1831HLA-DRB1*10:01 increased the risk of immediate
hypersensitivity at a genome-wide level (odds ratio, 2.96; P 5
4.1 3 1029). No association with HLA-DRB1*10:01 was
identified in 268 patients with delayed hypersensitivity reactions
to b-lactams.
Conclusions: HLA-DRB1*10:01 predisposed to immediate
hypersensitivity reactions to penicillins. Further work to
identify other predisposing HLA and non-HLA loci is required.
(J Allergy Clin Immunol 2021;147:1830-7.)
Key words: Type I hypersensitivity, b-lactams, penicillins, cephalo-
sporins, allergy, anaphylaxis, pharmacogenomics
b-Lactam (BL) antibiotics cause a wide spectrum of hypersen-
sitivity reactions (sometimes termed allergy). The self-reported
incidence of BL allergy ranges from1% to>10%,1 but in clinic pop-
ulations, most patients (;95%) are not found to be truly allergic
with validated skin testing and oral challenge. Indeed, a high pro-
portion are intolerant2 as adverse effects such as diarrhea after the
use of BLs are often mistakenly reported as allergy by patients.
True BL hypersensitivity reactions are classified according to
the time of onset of the reaction following drug intake.3 Immedi-
ate hypersensitivity reactions develop in minutes or hours after
drug intake and are due to cross-linking of specific IgE molecules
on the mast cell surface with release of vasoactive mediators
such as histamine leading to vasodilation, increased vascular
permeability, and smooth muscle contraction.4 Clinically this is
manifested as urticaria, angioedema, bronchospasm, and hypo-
tension. Anaphylaxis is the most severe and feared form of imme-
diate hypersensitivity. By contrast, delayed hypersensitivity
reactions occurring >6 hours after dosing are typically T-cell-
mediated and have variable manifestations including maculopap-
ular exanthem, drug reaction with eosinophilia and systemic
symptoms, and Stevens-Johnson syndrome/toxic epidermal
necrolysis.3
Medicines are among the main cause of fatal anaphylaxis with
a mortality rate higher than with other agents.5 Penicillins and
cephalosporins are still the 2 most common drug classes associ-
ated with anaphylaxis,6 with penicillins having a higher incidence
(1-5 per 100,000)7 compared with cephalosporins.1 Cross-
reactivity between penicillins, cephalosporins, and other BLs
not sharing an R1 or R2 side chain is now thought to be <2%.8,9
Potential clinical risk factors for immediate hypersensitivity
reactions are family history, atopy, concomitant virus infections,
and the route of administration.10 Genetic predisposing factors
have also been identified:10 the most comprehensive was an anal-
ysis of 107,398 single nucleotide polymorphisms (SNPs) that
identified that the HLA-DRA locus may protect against
penicillin-induced immediate hypersensitivity reactions.11 To
further investigate the role of genetic factors in BL-induced
immediate hypersensitivity reactions, we have undertaken a
genome-wide association study of the largest deeply phenotyped
patient cohort assembled so far.METHODS
Cases
All subjects were recruited between 2009 and 2013 as part of International
Consortium on Drug Hypersensitivity, involving 5 recruitment centers
worldwide (Australia, France, Italy, Spain, and United Kingdom). The studywas approved by ethics committees in all countries, and all patients gave
written informed consent.
We recruited 662 patients (the discovery cohort) with a diagnosis of
immediate hypersensitivity to BL antibiotics (Table I). The diagnosis of im-
mediate hypersensitivity was made in specialist allergy clinics, as per pub-
lished criteria.12 All patients required immunological assessment (total and
specific IgE, skin testing including skin prick test and intradermal and/or
oral provocation) as part of the inclusion criteria. Independent adjudication
of all cases was undertaken by N.H.S. and P.S.F. For replication of any signals,
we separately recruited another 98 patients with immediate hypersensitivity
from a clinic in Spain, diagnosed according to the same criteria.
To determine specificity of any signals identified in patients with imme-
diate hypersensitivity, we also evaluated 268 patients with delayed hypersen-
sitivity reactions across multiple BLs. The diagnosis again was in accordance
with published guidance,12 and all cases were adjudicated byN.H.S. and P.S.F.
We also included an additional 17 BL-induced delayed hypersensitivity reac-
tion cases analyzed in Shen et al.13
Controls
We used general population samples as study controls. This comprised
9217 European ancestry controls from multiple available sources enriching
the group with Spanish, Italian, and north European origin samples because
casesweremainly recruited from those countries.We used theWellcomeTrust
Case Control Consortium (http://www.wtccc.org.uk); the Population Refer-
ence Sample (POPRES),14 PGX4000119,13 LAM30004,13 and Spanish
Bladder cancer cohort (phs000346.v1)15 from the Database of Genotypes
and Phenotypes (dbGaP); Hypergenes cohort (http://www.hypergenes.eu/);
the National Spanish DNA Bank (http://www.bancoadn.org/); and Toscani
in Italia ([TSI] HapMap data) to obtain ancestry control data. In addition,
we also recruited a group of 137 penicillin-tolerant controls from Italy.
Genotyping
Genome-wide genotyping of DNA extracted from whole blood was
performed at the Broad Institute (Boston, Mass) for 662 cases with BL-
induced immediate hypersensitivity and 268 caseswith delayed hypersensitivity
reaction, and from 137 penicillin-tolerant controls from Italy. In 474 (354 BL-
induced immediate and 120 BL-induced delayed) cases, the Illumina Infinium
HumanCoreExome BeadChip (Illumina, Inc, San Diego, Calif) was used while
for 439 (308 BL-induced immediate and 131 BL-induced delayed) cases, the
Illumina HumanOmniExpress BeadChip was used. In this last batch, we also
genotyped 137 Italian penicillin-tolerant controls. In addition, the BL-induced
delayed case group also included 17 BL-delayed hypersensitivity cases
previously genotyped by the Illumina 1M Duo chip, extracted from a larger
Stevens-Johnson syndrome/toxic epidermal necrolysis study that included
multiple drugs, as described by Shen et al.13 Other control cohorts were publicly
available (see Table E1 in this article’s Online Repository at www.jacionline.
org). For each of the genotyping cohort, standard quality control was conducted
at both single marker and subject levels as previously described.13 This was fol-
lowed by SNP and HLA imputation and amino acid analysis (see the Methods
section in this article’s Online Repository at www.jacionline.org).Replication cohort SNP and HLA genotyping
The top associated imputed SNPs were validated by SNP genotyping using
either TaqMan, SNP genotyping assays (Thermo Fisher Scientific, Paisley,









Female, n (%) 416 (62) 56 (57) 174 (64)
Age (y) mean 6 SD (% missing) 42.0 6 16 (27) 51.4 6 12.3 (0) 44.5 6 20 (73)
History of allergies, % (no. with available information) 31 (658) 9 (98) 30.6 (268)
No. of ADRs, mean 6 SD (no. with available information) 1.1 6 0.3 (659) 1.2 6 0.5 (98) 1 6 0.2 (251)
Autoimmune disease diagnosis, % 9 6 7
Positive skin test, % (total no. tested) 85 (578) 78 (67) 93 (204)
Positive prick test, % (total no. tested) 45 (142) 37 (82) 82 (207)
Positive oral provocation/rechallenge, % (total no. tested) 76 (106) 65 (20) 94 (17)
Clinical symptoms, n (%)
Immediate hypersensitivity manifestations* 662 (100) 98 (100) —
AGEP — — 14 (5)
DRESS — — 7 (3)
Mild reactions including maculopapular exanthem — — 212 (79)
SJS/TEN — — 36 (13)
Drug class, n (%)
Penicillin 501 (75) 98 (100) 246 (92)
Cephalosporin 162 (25) — 20 (7.5)
Other BLs — — 2 (0.01)
Suspected causal drug
Amoxicillin 165 (25) 65 (66) 77 (29)
Ampicillin 36 (5) — 54 (20)
Bacampicillin 20 (3) — 21 (8)
Cefaclor 23 (3) — —
Cefazolin 17 (3) — 4 (1.5)
Cefotaxime 17 (3) — —
Ceftazidime 18 (3) — 1 (0.4)
Ceftriaxone 52 (8) — 4 (1.5)
Cefuroxime 14 (3) — 2 (0.7)
Co-amoxiclav 218 (33) 26 (26) 70 (26)
Phenoxymethylpenicillin 24 (4) 7 (7) 5 (2)
Piperacillin 18 (3) — 5 (2)
Other 41 (6) — 25 (9)
ADRs, Adverse drug reactions; AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; SD, standard deviation; SJS/
TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
*See text for nature of clinical manifestations.
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Hamburg, Germany). High-resolution genotyping of HLA-A, HLA-B, HLA-C,
DRB1, DQA1, and DQB1 was performed by Histogenetics (Ossining, NY).
Sequencing data files were analyzed using Histogenetics’ proprietary analysis
software (Histomatcher andHistoMagic) for HLA genotype calling. Allele as-
signments are based on IMGT/HLA Database (release version 2.21.0, dated
April 2008; http://www.ebi.ac.uk/imgt/hla/).Statistical analysis
The effect of population structure was assessed through principal
component analysis using the smartPCA program from the EIGENSTRAT
package (version 3.0; Alkes Price, Harvard T.H. Chan School, Boston,
Mass).16 Single marker and haplotype association analyses and heterogeneity
test analyses were carried out by PLINK 1.07.17 The statistical association of
each marker, HLA alleles and SNPs, was determined in a logistic regression
framework with scores for the first 7 principal components as covariates under
an additive model using PLINK. We used the same statistical test for subpop-
ulation analyses, using the 2, 7, and 10 most significant principal components
as covariates in Italian, Spanish, and North European populations, respec-
tively. We set the genome-wide traditional significance P-value threshold to
5.0 3 1028 to correct for multiple testing and MHC-wide significance
threshold to 2.0 3 1024 to correct for total number of predicted alleles.
Whenwe obtained genome-wide significant signals, we tested for independent
effects from the neighboring variants by including themost associated variants
as a covariate and then testing the significance of others in the region. Alldetailed analyses and Manhattan plots were performed with R (version
3.0.2; R Foundation, Vienna, Austria). Regional plots were drawn by Locus-
Zoom.18 Meta-analysis was performed using a fixed-effect model in themeta-
for package (http://www.metafor-project.org/doku.php/metafor).RESULTS
Patient cohorts
The clinical characteristics of the patients are shown in Table I.
Clinical manifestations in the discovery cohort included angioe-
dema (35%), bronchospasm (24%), and urticaria (34%), while
hypotension was reported in only 4% of cases. The length of re-
action in patients with immediate hypersensitivity was 2 to 11
days, while it ranged from 21 to 26 days for patients with delayed
hypersensitivity reactions. Patients were included if they had pos-
itive diagnostic assessment, as highlighted in Table I. Penicillins
accounted for 75% of cases, with the most common culprit drug
being amoxicillin accounting for 58% of cases in the discovery
cohort.Association with immediate reactions to BLs
We first conducted a genome-wide association study on 662
patients of European descent with immediate hypersensitivity
TABLE II. The most significantly associated variants for immediate hypersensitivity reactions to BLs







reference cohort OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
HLA-DRB1*10:01 0.03 0.008 0.008 2.95 (1.99-4.36) 6.0 3 1028 — — 0.60 (90.19-1.85) .37
HLA-DQA1*01:05 0.03 0.01 0.01 2.93 (1.92-4.46) 5.4 3 1027 — — 0.79 (0.32-1.91) .60
rs71542416 0.03 0.006 0.008 5.17 (3.40-5.17) 1.2 3 10214 8.22 (2.68-25.23) .0002 — —
rs114632839 0.25 0.367 0.40 0.77 (0.67-0.89) .0003 0.69 (0.60-0.80) 1.1 3 1026 0.68 (0.59-0.79) 6.1 3 1027
Minor allele frequency for external data obtained from allelefrequncy.net for HLA alleles or GnomAD for SNPs. ORs are of the logistic regression model, correcting for population
stratification. P values are logistic regression P.
*HLA haplotype was HLA-DRB1*10:01–HLA-DQA1*01:05.
The marker rs114632839 has merged with rs3135392.
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matched for ethnicity. The total number of SNPs, which were
included in the analyses after quality control, was 4,265,742. The
cases clustered within 3 major groups (Italian, Spanish, and
Northern European) (see Fig E1 in this article’s Online Reposi-
tory at www.jacionline.org) in keeping with the self-reported
ethnicity.
A genome-wide significant association was identified within
the Class II HLA region, rs71542416 being the top hit (odds ratio
[OR], 5.17; 95%CI, 3.40-5.17;P5 23 10214) (Table II, Fig 1,A,
and see Fig E2 in this article’s Online Repository at www.
jacionline.org). The frequency of rs71542416 in our control pop-
ulation was comparable with that reported in publicly available
sources (Table II). HLA allele imputation using HLA genotype
imputation with attribute bagging, or HIBAG,19 showed the
HLA-DRB1*10:01 (OR, 2.95; 95% CI, 1.99-4.36; P 5
6.0 3 1028) and HLA-DQA1*01:05 (OR, 2.93; 95% CI, 1.92-
4.45; P 5 5.4 3 1027) alleles to be significantly associated
with the immediate reactions, with consistent ORs (Table II)
and were tagged by rs71542416 (r2 5 0.76). Haplotype analysis
identified that HLA-DRB1*10:01 was a risk factor even without
theHLA-DQA1*01:05 allele (see Table E2 in this article’s Online
Repository at www.jacionline.org). HLA-DRB1*10:01 was seen
in 3% of cases and <1% of controls. The frequency of the HLA
alleles within the Italian penicillin-tolerant controls was 10 times
less than in the Italian general population (0.1% vs 1%).
The HLA allele effect size was similar across the 3 major
clusters (heterogeneity test, P5 .11) (Table III). The positive pre-
dictions in cases were fully validated by direct HLA typing. An
additional 67 cases with low-quality predictions in both the loci
were also typed. Among them, we found only 1 positive carrier
for HLA-DRB1*10:01. All cases were also genotyped for
rs71542416—this showed a concordance of 99% between typed
and imputed genotypes of rs71542416. HLA-DRB1*10:01 co-
occurred with rs71542416 in 89% of theHLA-DRB1*10:01–pos-
itive patients, while 12% of all cases carried rs71542416 alone.
Including rs71542416 or the HLA alleles as covariates revealed
a residual protective effect of the HLA-DRA locus, tagged by
rs114632839, an intronic gene variant, in accordance with the
findings of Gueant et al11 (Table II and see Figs E3 and E4, A
in this article’s Online Repository at www.jacionline.org).
Interestingly Genotype-Tissue Expression Program, or GTEx
(Common Fund, National Institutes of Health, Bethesda, Md),
analysis revealed that this variant was a strong expression quanti-
tative trait loci (QTL) for HLA-DRB5 (P 5 5.3 3 10223) and
splicing QTL for the HLA-DRB1 (P 5 1.1 3 10216), HLA-
DRB5 (P 5 1.1 3 10216) and HLA-DRB6 (P 5 1.1 3 10216)loci with the minor alleles showing a lower intron excision ratio.
Both effects were detected in whole blood and shared across other
tissues (Fig E4, B).
A replication cohort of 98 patients with anaphylaxis induced by
either amoxicillin or amoxicillin-clavulanate (Table I) was re-
cruited separately from Spain. We identified 7 individuals who
were positive for HLA-DRB1*10:01, as confirmed by HLA
typing. Comparison using the 11 Spanish HLA-typed cohorts re-
ported at allelefrequency.net provided a total of 3137 Spanish
subjects (see Fig E5 in this article’s Online Repository at www.
jacionline.org) as ethnically matched population controls. This
analysis replicated the association with an OR of 2.80 (95% CI,
1.17-6.71; Fisher exact test, P 5 .016) (Fig 1, B).
Meta-analysis of the discovery and replication cohorts showed
thatHLA-DRB1*10:01 increased the risk of immediate hypersen-
sitivity at a genome-wide level (OR, 2.96; 95%CI, 1.99-4.37;P5
4.13 1029) (Fig 1, B). The sensitivity and specificity of the allele
is 0.06 and 0.98, respectively, while the positive and negative pre-
dictive values are 17% and 94%, respectively.
The most significantly associated amino acid with immediate
hypersensitivity reactions was glutamate at position 10 (OR, 2.72;
95%CI, 1.81-4.08; P5 1.43 1026) (see Table E3 in this article’s
Online Repository at www.jacionline.org). Amoxicillin,
amoxicillin-clavulanic acid, and phenoxymethylpenicillin
showed the highest effect size (see Table E4 in this article’s
Online Repository at www.jacionline.org). Glutamate-10 co-
occurred with other amino acids (arginine-30, valine-31,
alanine-38, tyrosine-40, proline-231, glutamine-166) that had
the same frequency in cases and controls as glutamate-10 and
HLA-DRB1*10:01 (Table E3). However, association with these
amino acids disappeared after condition for either glutamate-10
or HLA-DRB1*10:01 (Table E3). Interestingly, glutamate-10
co-occurred with the shared epitope RRA at positions 70, 71
and 74, previously associated with seropositive rheumatoid
arthritis20 and specific for the HLA-DRB1*10:01 allele. The
ERRA haplotype increased risk (OR, 2.72; P 5 1.4 3 1026)
equivalent to that seen with glutamate-10 alone. None of the other
risk/protective amino acid motifs for seropositive rheumatoid
arthritis20 spanning positions 70 to 74 in the DRB1 locus (such
as QRRAA risk motif or DERAA and DRRAA protective motifs)
were associated with our phenotype.HLA analysis in patients with delayed
hypersensitivity reactions
To determine whether the association with HLA-DRB1*10:01
was limited to patients with immediate hypersensitivity reactions,
FIG 1. Genomic data in patients with immediate hypersensitivity reactions. A, Manhattan plot displaying
the association analysis undertaken in patients with immediate hypersensitivity reactions to BLs (n 5
662). SNPs in green have a significance level <53 1026 and red have a significance level <53 1028. B, Forest
plot showing the effect size of the association betweenHLA-DRB1*10:01 and immediate reactions in the dis-
covery and replication cohorts. For each analysis, the OR of the association is reported with 95% CI. The
dimension of the squares is proportional of the number of cases.
TABLE III. The association between HLA-DRB1*10:01 and rs71542416, and BL-induced immediate hypersensitivity reactions
across the different nationalities
Ethnic cluster No. of cases*
Minor allele frequency
OR (95% CI) P valueCases Controls
HLA-DRB1*10:01
Italians 352 0.021 0.012 2.33 (1.15-4.73) .02
Spanish 226 0.049 0.014 3.81 (2.27-6.42) 4.74 3 1027
Northern Europeans 61 0.025 0.004 3.93 (1.17-13.21) .03
rs71542416
Italians 352 0.02 0.007 4.33 (1.98-9.49) .0002
Spanish 226 0.05 0.008 6.80 (3.89-11.87) 1.69 3 10211
Northern Europeans 61 0.02 0.004 4.42 (1.29-15.13) .02
OR and P value as defined in Table II.
*Numbers represent homogeneous populations within clusters after principal component analysis.
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ety of BLs (Table I) using the same control set (Fig E1, B). No as-
sociation was identified for HLA-DRB1*10:01 (n 5 249; OR,
1.34; 95% CI, 0.55-3.26; P 5 .5).Drug-specific associations with immediate
hypersensitivity
HLA-DRB1*10:01 was associated with penicillins as a class
(OR, 3.07), but not with cephalosporins (Table IV). Among the
penicillins, the strongest signals were for amoxicillin (OR,3.48), amoxicillin clavulanic acid (OR, 2.85), and phenoxyme-
thylpenicillin (OR, 6.66) (Table IV). When we combined amoxi-
cillin and amoxicillin clavulanic acid cases (assuming that
amoxicillin rather than clavulanic acid was the culprit), the
OR was 3.1 (95% CI, 2.01-4.85; P 5 4.0 3 1027). Additional
drug-specific HLA allele associations that we identified will
need confirmation (see Tables E5 and E6 in this article’s Online
Repository at www.jacionline.org).
In the drug-specific analysis, a genome-wide signal
(rs71437970) on chromosome 13 upstream of SLC15A1 (see Fig
E6 in this article’s Online Repository at www.jacionline.org) was
TABLE IV. Effect size of the association of HLA-DRB1*10:01 with immediate hypersensitivity reactions broken down by drug
classes and individual drugs
Drug Ethnicity* No. of cases Case MAF OR (95% CI) P value
Cephalosporins Caucasian 162 0.019 2.03 (0.82-5.07) .13
Cefaclor Caucasian 23 0 — —
Cefazolin Caucasian 17 0.059 6.12 (1.32-28.30) .02
Cefotaxime Italian 17 0 — —
Ceftazidime Italian 17 0 — —
Ceftriaxone Italian 48 0.010 1.05 (0.13-8.33) .96
Cefuroxime Caucasian 14 0.050 2.90 (0.37-22.76) .31
Penicillins Caucasian 501 0.036 3.07 (2.04-4.62) 7.42 3 1028
Amoxicillin Caucasian 166 0.042 3.48 (1.92-6,28) 3.74 3 1025
Ampicillin Italian 29 0.014 1.98 (0.25-15.79) .52
Co-amoxiclav Caucasian 218 0.034 2.85 (1.60-5.10) .0004
Phenoxymethylpenicillin Caucasian 25 0.080 6.66 (2.14-20.79) .001
Piperacillin Caucasian 18 0.028 2.32 (0.29-18.78) .43
Bacampicillin Italian 21 0.024 2.09 (0.26-17.03) .49
MAF, Minor allele frequency. OR and P value as defined in Table II.
*Ethnicity—Caucasian is applied to patients of Spanish, Italian, and Northern European descent and confirmed by principal component analysis. Where only 1 nationality was
available for a particular drug, this is indicated and only appropriate matching controls were chosen.
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(Table E6). This association was shared across the European sub-
populations and with amoxicillin-clavulanate cases (see Tables
E7 and E8 in this article’s Online Repository at www.jacionline.
org). However, we failed to replicate the association, with an allele
frequency that was lower than that observed in Spanish controls
(0.007 vs 0.04).DISCUSSION
Wehave identified an association between the SNP rs71542416
and immediate hypersensitivity reactions to penicillins. The SNP
does not affect gene expression in GTEx but is in linkage
disequilibrium with HLA-DRB1*10:01 and HLA-DQA1*01:05.
Haplotype analysis identified that HLA-DRB1*10:01 was a risk
factor even without the HLA-DQA1*01:05 allele suggesting
that HLA-DRB1*10:01 may be the predominant driver of the as-
sociation. However, 12% of cases carried rs71542416 but were
negative for HLA-DRB1*10:01, suggesting that the SNP may
be a tag for other rare HLA alleles, which is consistent with
the hypothesis of Heap et al21 who showed an association
between HLA-DQA1-HLA-DRB1 variants and thiopurine-
induced pancreatitis.
The association with HLA-DRB1*10:01 and rs71542416 was
most pronounced in the Spanish cohort (Table III), but given
that the ORs were of similar magnitude in all populations stud-
ied, there was overlap in the CIs, and the prevalence of the SNP
and HLA allele, our findings can be generalized across the
European subethnicities studied (Table III). However, further
studies will be needed in both European and non-European pop-
ulations to determine the global relevance of this association.
Additionally, the association was limited to immediate reactions
and was not observed with the delayed hypersensitivity
reactions, highlighting the specific nature of the association.
Evaluation of drug-specificity showed associations with
amoxicillin, amoxicillin-clavulanate, and phenoxymethylpeni-
cillin. However, given the limited sample size with the other
penicillins, we cannot exclude the possibility of an association
with all penicillins (Table IV). Similarly, we did not find anassociation with cephalosporins, but this may also be because
of a lower sample size.
The clear strength of our study is that all patients were deeply
phenotyped: there was a clear clinical history with a temporal
relationship to drug intake, and the diagnosis was confirmed
immunologically by skin testing and/or oral provocation. Such
deep phenotyping is important because many patients claim to
be allergic to penicillin, but very few are; of those claiming to
be allergic, <1 in 20 have an acute reaction to an oral challenge
(the gold standard clinical test to confirm an IgE-mediated
reaction).22
Our data add to the increasing evidence of HLA in predisposing
to different clinical phenotypes of drug hypersensitivity
reactions.23 The most well-known of these associations is HLA-
B*57:01 and abacavir hypersensitivity,24 which has been imple-
mented into clinical practice and has resulted in a significant
reduction in abacavir hypersensitivity.25 It is important to note
that most of the HLA associations identified to date have been
with delayed hypersensitivity reactions.23 However, more recent
studies have identifiedHLA alleles as predisposing factors for im-
mediate reactions. For instance,HLA-DRB1*07:01 is a risk factor
for the development of anti-asparaginase antibodies and immedi-
ate reactions.26 Our data, which show thatHLA-DRB1*10:01 pre-
disposes to immediate hypersensitivity, are also consistent with
the pathogenesis of immediate reactions where the interaction be-
tweenB cells and CD41/TH2-positive cells, throughHLAClass II
alleles, is central to the immunoglobulin switching that leads to
the generation of specific IgE antibodies. Different HLA alleles
have been associated with other types of immune-mediated reac-
tions caused by BLs. For example, HLA-B*57:01 predisposes to
flucloxacillin-induced cholestatic hepatitis,27 while liver injury
caused by amoxicillin-clavulanate is associated with the Class
II HLA haplotypeHLA-DRB1*1501-DQB1*0602.28 Mechanistic
studies undertaken in our laboratory have shown that drug-
specific, HLA-restricted T cells can be isolated from patients
with a past history of liver injury due to flucloxacillin29 and amox-
icillin-clavulanate.30 It will be valuable to conduct similar studies
in patients with a history of penicillin-induced immediate reac-
tions to understand the mechanistic basis of the association with
HLA-DRB1*10:01.
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association between SLC15A1 gene variants and amoxicillin-
induced immediate reactions. SLC15A1 encodes the human pep-
tide transporter 1, which is known to transport amoxicillin.31
Therefore, it is plausible that variation in the activity of
human peptide transporter 1 could result in altered amoxicillin
pharmacokinetics and thereby increase risk of a type I reaction.
However, we were not able to replicate this finding, and further
work (including functional studies) to understand whether this
gene is important in predisposing to immediate reactions will
be required.
What are the clinical implications of this finding? Given the
rarity of penicillin-induced anaphylaxis, the low population
prevalence and sensitivity of HLA-DRB1*10:01, and the very
wide usage of penicillins, the prospective use of this allele in
screening patients before penicillin prescription would not be
practical or feasible in terms of both the high numbers needed
to test to prevent 1 case and patients unnecessarily excluded
from therapy. However, this association of immediate penicillin
hypersensitivity withHLA-DRB1*10:01may providemuch novel
insights into the mechanisms of immediate reactions associated
with penicillins, including the mechanisms of sensitization and
natural loss or waning of penicillin, which is known to occur
over time. Moreover, the higher negative predictive value of the
allele (94%) may be of use in risk stratifying patients where peni-
cillin cannot be excluded as an etiological agent in the setting of
an immediate reaction.
Our study has limitations. First, the overall sample size is small
compared with that used in complex diseases, but it is larger than
that used in many pharmacogenomic studies. Our efforts to
identify deeply phenotyped patients in this studywas a result of an
extensive international collaboration highlighting the difficulties
in achieving large sample sizes in pharmacogenomic studies.
Furthermore, we were unable to perform permutation testing to
validate the replication P value for HLA-DRB1*10:01. Second,
because we used population controls, we could not adjust for
self-reported ethnicity, but this is unlikely to have had a major
impact as we accounted for this through an analysis of population
stratification (Fig E1). Third, matching cases and controls for age,
sex, and other comorbidities was not possible because of the use
of population controls, and because sex could not be determined
due to the absence of X chromosome SNP data. Whether this im-
pacts on the association with the genetic signals identified by us
will require further study.
In summary, we have for the first time reported an association
ofHLA-DRB1*10:01 carriage in deeply immunologically pheno-
typed European ancestry individuals with penicillin-induced im-
mediate type I hypersensitivity reactions. However, we cannot
exclude the possibility of other HLA alleles or HLA haplotypes
also being important in conferring susceptibility in some patients,
and therefore further work in both European and non-European
patients is required to identify other HLA alleles, and also
whether HLA-DRB1*10:01 is universally important. It is also
interesting to note that we also identified that rs114632839, which
is a proxy for the HLA-DRA locus, protected against the develop-
ment of immediate hypersensitivity reactions to BLs, consistent
with a previous study.11 rs114632839 is an expression QTL and
splicing QTL for several HLA loci, suggesting that predisposition
to immediate hypersensitivity to penicillins is likely to be com-
plex and mediated by a combination of susceptibility and protec-
tive HLA and non-HLA alleles. Clearly we have reportedassociations, and proof of causality will require a full understand-
ing of the immunopathogenesis of initial sensitization to peni-
cillin, and in particular, the mechanism of antigen presentation
(including the relative importance of the BL ring vs the side
chains) and interaction with CD41 T cells that ultimately leads
to IgE-switching and the generation of hapten-specific IgE
antibodies.
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Clinical implications: This novel insight into the mechanisms of
immediate reactions associated with penicillins may be of use in
risk stratifying patients where penicillin cannot be excluded as
an etiological agent.REFERENCES
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METHODS
Imputation procedure
Prephasing and imputation was performed in batches by dividing the cases
and controls according to the genotyping platform. For each batch, we first
prephased the genotype scaffold using SHAPEIT (version v2.r727).E1 Impu-
tation was then undertaken using IMPUTE2 (version 3)E2 using the reference
panel from the 1000 Genomes Project (release v3).E1 We used the ‘‘all ances-
tries’’ reference panel to improve the quality of the imputation especially of
lower frequency variants.E2 For downstream analysis, we used best-guess ge-
notypes retaining imputed genotypes with posterior probability >0.9. In the
combined dataset, we then retained SNPs with: (1) no significant difference
in missingness between cases and controls (P > .0001); (2) no significant de-
viation from Hardy-Weinberg equilibrium (P > .0001); (3) < 5% missing ge-
notypes in all batches; (4) imputation information score >0.8 in all batches;
and (5) MAF in the European descent haplotypes from the 1000 Genomes
Project reference panel of at least 0.01. Finally, we compared SNP allele fre-
quencies in controls between genotyping platforms. Specifically, we tested for
association of genotyping platforms with SNPs in same ethnicity controls in a
logistic regression framework, under an additive genetic model, with
adjustment for principal components from smartPCA to account for popula-
tion structure. SNPs with nominal evidence of association (P < .0001) were
excluded. Sex chromosomes and mitochondria were not imputed.
For each batch, HLA alleles were inferred using HIBAGE3 using the refer-
ence predictor panels specific for the genotyping chip and Caucasian ancestry.
Amino acid changes were inferred using SNP2HLA utilizing the reference
data collected by the Type 1 Diabetes Genetics Consortium.E4
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FIG E1. Scatterplot representing the first 2 principal components (PCs) of the current study cohorts, cases
and controls: BL-immediate hypersensitivity reactions (A) and BL-delayed hypersensitive reactions (B).
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FIG E2. The figure shows the QQ plot for the current analysis. The inflation
factor is 1.09.
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FIG E3. Regional plots of the MHC region for the conditioned analysis on HLA-DRB1*10:01/HLA-
DQA1*01:05 haplotype (A) and on rs71542416, the most associated SNP (B).
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FIG E4. Violin plots from the GTEx website for expression QTL (A) and splicing QTL (B) effects of
rs114632839 in whole blood.
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FIG E5. Spanish studies reported on allelefrequency.net used as replication control set.
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FIG E6. Regional plot of the chromosome 13 signal associated with
amoxicillin-induced immediate hypersensitivity in the discovery cohort.
The horizontal axis shows SNPs along the chromosomal region and the
vertical axis shows the (2log10 transformed) observed P value. SNPs are
color-coded to depict their linkage disequilibrium (LD) with the top SNP,
shown in purple. Estimated recombination rates are plotted on the right
vertical axis in cyan to reflect the local LD structure.
J ALLERGY CLIN IMMUNOL
MAY 2021
1837.e7 NICOLETTI ET AL
TABLE E1. Genotyping details of the control cohorts
Cohort No. of samples Genotyping Array
WTCCC 4824 Illumina 1M BeadChip
phs000346.v1 (dbGaP) 2072 Illumina 1M BeadChip
Hypergenes 901 Illumina 1M BeadChip
LAM30004 collection 60 Illumina 1M BeadChip
National Spanish DNA Bank 173 Illumina 1M Duo/Illumina Infinium HumanCoreExome BeadChip
222 Illumina Infinium HumanCoreExome BeadChip
iSAEC Italian penicillin-tolerant controls 137 Illumina HumanOmniExpress BeadChip
PGX40001 collection 85 Illumina 1M Duo BeadChip
TSI 88 Illumina 1M Duo BeadChip
POPRES 655 Illumina 1M Duo BeadChip
iSAEC, International Serious Adverse Events Consortium; WTCCC, Welcome Trust Case Control Consortium.
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TABLE E2. Effect size for the association with the HLA-DRB1*10:01 and HLA-DQA1*01:05 haplotypes
HLA-DRB1*10:01 HLA-DQA1*01:05
MAF
OR P valueCases Controls
P P 0.03 0.01 2.93 .000001
P A 0.005 0.001 2.84 .04
A, Absence of allele in the haplotype; P, presence of allele in the haplotype. OR and P value as defined in Table II. No individuals carried HLA-DQA1*01:05 alone.
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TABLE E3. Most significant association results for amino acids in HLA molecules and risk of immediate hypersensitivity to
penicillins





Position AA Cases Controls OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
10 E 0.03 0.008 2.72 (1.81-4.09) .000001 — — — —
30 R 0.03 0.008 2.67 (1.78-4.01) .000002 — — — —
31 V 0.03 0.008 2.67 (1.78-4.01) .000002 — — — —
38 A 0.03 0.008 2.67 (1.78-4.01) .000002 — — — —
40 Y 0.03 0.008 2.67 (1.78-4.01) .000002 — — — —
231 P 0.03 0.008 2.53 (1.68-3.8) .000008 — — 0.4 (0.04-4.2) .44
166 Q 0.03 0.008 2.52 (1.68-3.79) .000009 — — — —
11 V 0.17 0.15 1.42 (1.19-1.69) .00008 1.28 (1.06-1.55) .008 1.29 (1.07-1.55) .008
37 Y 0.41 0.3 1.27 (1.11-1.44) .0004 1.21 (1.06-1.38) .005 1.21 (1.06-1.38) .005
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TABLE E4. Association between glutamate at position 10 in the HLA-DRB1*10:01 molecule and risk of immediate hypersensitivity
stratified by class of BL and individual molecules
Drug Ethnicity No. of cases Case MAF OR (95% CI) P value
Cephalosporins Caucasian 162 0.01 1.61 (0.59-4.33) .34
Cefaclor Caucasian 23 — — —
Cefazolin Caucasian 17 0.06 6.26(1.35-29.98) .01
Cefotaxime Italian 17 — — —
Ceftazidime Italian 17 — — —
Ceftriaxone Italian 48 — — —
Cefuroxime Caucasian 14 0.04 2.73 (0.34-21.69) .34
Penicillins Caucasian 501 0.03 2.85 (1.85-4.35) 1.2 3 1026
Amoxicillin Caucasian 166 0.04 3.31 (.80-6.10) .0001
Ampicillin Italian 29 0.01 1.88 (0.23-6.10) .54
Co-amoxiclav Caucasian 218 0.03 2.44 (1.31-4.51) .004
Phenoxymethylpenicillin Caucasian 25 0.08 7.35 (2.37-22.95) .0005
Piperacillin Caucasian 18 0.03 2.17 (0.26-17.78) .46
Bacampicillin Italian 21 0.02 1.98 (0.24-16.10) .52
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TABLE E5. Effect size of the association of the most significant HLA risk alleles in the amoxicillin clavulanic acid analysis
MAF Association analysis
Association conditioned for HLA
haplotype
Cases Controls OR (95% CI) P value OR (95% CI) P value
HLA-DRB1*01:03 0.02 0.007 5.21 (2.45-11.09) 1.8 3 1025 5.45 (2.56-11.61) 1.1 3 1025
HLA-DQA1*01:05 0.03 0.01 3.42 (1.90-6.15) 4.0 3 1025 — —
HLA-DPB1*13:01 0.06 0.02 2.24 (1.47-3.42) 1.8 3 1024 2.28 (1.49-3.48) 1.4 3 1024
HLA-DRB1*10:01 0.03 0.008 2.85 (1.60-5.10) 3.9 3 1024 — —
OR and P value as defined in Table II.
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OR (95% CI) P valueCases Controls
Italians 96 0.005 0.002 4.08 (0.39-42.02) .2
Spanish 101 0.040 0.005 9.53 (4.00-22.71) 3.5 3 1027
Northern Europeans 17 0 0.009 — —
OR and P value as defined in Table II.
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TABLE E7. Effect size of rs71437970 with immediate hypersensitivity reactions broken down by drug classes and individual drugs
Drug Ethnicity* No. of cases Case MAF OR (95% CI) P value
Cephalosporins Caucasian 162 0.05 0.64 (0.77-1.81) .77
Cefaclor Caucasian 23 0.09 0.58 (0.34-4.90) .34
Cefazolin Caucasian 17 0.06 0.34 (0.63-5.81) .63
Cefotaxime Italian 17 — — —
Ceftazidime Italian 17 — — —
Ceftriaxone Italian 48 — — —
Cefuroxime Caucasian 14 0.05 0.18 (0.76-10.15) .76
Penicillins Caucasian 501 0.08 1.78 (1.36-2.32) 2.3 3 1025
Amoxicillin Caucasian 166 0.11 2.93 (2.05-4.19) 3.8 3 1029
Ampicillin Italian 29 0.02 0.29 (0.04-2.07) .22
Co-amoxiclav Caucasian 218 0.07 1.48 (0.99-2.21) .06
Phenoxymethylpenicillin Caucasian 25 0.02 1.59 (0.34-7.46) .56
Piperacillin Caucasian 18 0.11 2.13 (0.71-6,40) .18
Bacampicillin Italian 21 0.07 1.33 (0.39-4.51) .65
OR and P value as defined in Table II.
*Ethnicity—Caucasian is applied to patients of Spanish, Italian and Northern European descent and confirmed by principle component analysis. Where only 1 nationality was
available for a particular drug, this is indicated and only appropriate matching controls were chosen.
J ALLERGY CLIN IMMUNOL
VOLUME 147, NUMBER 5
NICOLETTI ET AL 1837.e14




OR (95% CI) P valueCases Controls
Italians 52 0.15 0.05 2.91 (1.59-5.32) .0005
Spanish 80 0.09 0.04 2.55 (1.42-4.57) .002
North Europeans 24 0.12 0.04 3.89 (1.54-9.86) .004
OR and P value as defined in Table II.
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